1 not yet recruiting, 1 unknown. 1 Phase 2, 1 Phase 3, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Unknown 1 |
| Phase 3 | 1 | Unknown 1 |
| Phase 4 | 1 | Not yet recruiting 1 |
Follow Ye Xu: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| FOLFOX Chemotherapy Combined With Fruquintinib and Serplulimab as First-Line Conversion Therapy for Initially Unresectable pMMR/MSS Colorectal Cancer Serplulimab, Fruquintinib, mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU) - Colorectal Cancer (Locally Advanced or Metastatic), Colorectal Cancer Microsatellite Stable (MSS) | Phase 4 | Not yet recruiting | Ye Xu | 42 | 2026-03-01 | 2026-03-03 |
| Alternating Systemic and Hepatic Artery Infusion Therapy As Adjuvant Treatment After Resection of Liver Metastases From Colorectal Cancer Floxuridine (FUDR),Dexamethasone (DXM), Heparin in combination with Oxaliplatin and Capecitabine (CapeOX) or in combination with Oxaliplatin and Leucovorin and 5-FU (mFOLFOX6), Oxaliplatin and Capecitabine (CapeOX) or Oxaliplatin and Leucovorin and 5-FU (mFOLFOX6) - Resected Liver Metastases From Colorectal Cancer | Phase 2 / Phase 3 | Unknown | Ye Xu | 432 | 2015-09-01 | 2015-08-20 |
Colorectal Neoplasms (1) · Neoplasm Metastasis (1)
Fluorouracil (2) · Leucovorin (2) · Oxaliplatin (2) · Capecitabine (1) · Floxuridine (1) · HMPL-013 (1) · Heparin (1)
China (2)